Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe NIH banner announcing terminology changes from “Artificial Intelligence” to “Super Intelligence” was removed. The page continues to show a 403 error instead of the study record.SummaryDifference1%

- Check18 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner was added announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe site footer revision number changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer site revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error, making the study record inaccessible. The prior study documents and related navigation have been removed, leaving only the error message and site footer.SummaryDifference19%

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.